RECRUITING

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

Talk to us

Conditions

Healthy VolunteersImmulina TMNatural Killer Cells (NK)Botanical Dietary SupplementInfluenzaDietary Supplementation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.

Official Title

Impact of Oral Immulina TM on Natural Killer Cell Activities and Other Biomarkers Associated with Increasing Host Immune Resilience to Upper Respiratory Viruses in Normal Human Volunteers

Quick Facts

Study Start:2022-07-01
Study Completion:2026-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05447078

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Ages 18-59 (study group 1) or ages 65 and above (study group 2)
  2. * Any chronic illness must be determined (by PI team) to be stable as evidenced by no changes in medical regimens within 30 days of enrollment.
  3. * Ability to comprehend the specific activities required to participate in the trial for which the participant is to be enrolled.
  1. * Any acute illness or significant injury within 30 days of enrollment.
  2. * Specific disease entities, which, in the opinion of the PI, could reasonably be assumed to have dysfunctional immune function as a component of their illness. These include HIV, AIDS, uncontrolled asthma, uncontrolled eczema, uncontrolled allergic rhinitis, uncontrolled urticaria, Rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, Type-1 diabetes mellitus, Guillain-Barr syndrome, Grave's disease, Hashimoto's thyroiditis, myasthenia gravis or vasculitis.
  3. * Active autoimmune diseases regardless of clinical stability. A history of autoimmune disease that is not considered active (i.e. no medical therapy for at least 1 year prior to enrollment) will not be excluded.
  4. * History of unstable chronic illness within 30 days of enrollment.
  5. * Unable/unwilling to commit to multiple research clinic visits which will be described in detail.

Contacts and Locations

Study Contact

Thomas M Hudson, RN
CONTACT
6014967808
tmhudson@umc.edu
Denise Montgomery, MT(ASCP)
CONTACT
6018155374
ddmontgomery@umc.edu

Principal Investigator

Gailen D Marshall, Jr., MD, PhD
PRINCIPAL_INVESTIGATOR
University of Mississippi Medical Center

Study Locations (Sites)

University of Mississippi Medical Center
Jackson, Mississippi, 39216
United States

Collaborators and Investigators

Sponsor: University of Mississippi Medical Center

  • Gailen D Marshall, Jr., MD, PhD, PRINCIPAL_INVESTIGATOR, University of Mississippi Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-07-01
Study Completion Date2026-06-30

Study Record Updates

Study Start Date2022-07-01
Study Completion Date2026-06-30

Terms related to this study

Keywords Provided by Researchers

  • Immulina TM
  • Natural Killer Cells (NK)
  • Botanical Dietary Supplement
  • Influenza
  • Dietary Supplementation

Additional Relevant MeSH Terms

  • Healthy Volunteers